ELV Stock Forecast & Price Target

Elevance Health maintains a strong market position as a leading health insurer in the U.S., serving 45 million medical members and offering a variety of insurance plans, including those under the Blue Cross Blue Shield brand in 14 states. The company is anticipated to achieve a Medicare Advantage margin of at least 2% in 2026, primarily due to effective pricing strategies and a strategic shift in membership composition, while its Medicaid segment showed improved margins in 4Q25 compared to prior guidance. Elevance's scale and local market share, combined with a robust growth pipeline in various sectors such as government-sponsored programs and integrated healthcare services, contribute to a favorable outlook for the company.

The analysis highlights a negative outlook for Elevance Health's stock driven by several fundamental concerns, including a projected decline of approximately 9% in Medicaid membership due to stricter eligibility requirements and adverse program changes in certain states, which negatively impacts their revenue stream. Furthermore, management has indicated a deterioration in Medicaid margins, with guidance suggesting a rough breakeven point for 2025 and a potential 100 basis points decrease in the implied margin run-rate for the second half of the year. Additionally, challenges in controlling medical costs and maintaining growth in the commercial market, along with lower expected earnings from the Carelon segment and a less favorable investment environment, contribute to the lowered earnings per share estimates for 2026.